News
Media
Conferences
Publication
Job Board
CME/CE
Partners
Editorial
Resources
Subscribe

Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

|Videos|May 17, 2021

You're Invited!

Author(s)John J. Miller, MD

John J. Miller, MD, formally invites you to the Annual Psychiatric Times® World CME Conference™.

John J. Miller, MD, invites you to join us for the hybrid model Annual Psychiatric Times® World CME Conference™ on September 30, 2021 through October 2, 2021. You can join via video call, or in San Diego, to earn CME credits.

Dr Miller is Medical Director, Brain Health, Exeter, NH; Editor in Chief, Psychiatric Times^TM; Staff Psychiatrist, Seacoast Mental Health Center, Exeter, NH; Consulting Psychiatrist, Exeter Hospital, Exeter, NH; Consulting Psychiatrist, Insight Meditation Society, Barre, MA.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

What Does Interventional Psychiatry Actually Mean? Reframing Non-Standard Treatments for Depression

What Does Interventional Psychiatry Actually Mean? Reframing Non-Standard Treatments for Depression

ByLara Shirikjian, MD

July 31st 2026

Gus Alva, MD, on Agitation, Psychosis, and Cognition in Alzheimer Disease

Gus Alva, MD, on Agitation, Psychosis, and Cognition in Alzheimer Disease

ByGustavo Alva, MD, DFAPA

July 31st 2026

schizophrenia

Real-World and Long-Term Trial Data Show Xanomeline/Trospium Cuts Hospitalizations, Antipsychotic Burden in Schizophrenia

ByPsychiatric Times Editors

July 30th 2026

visoot/Adobe Stock

What's New in Psychiatric Treatment? Highlights From the 2026 Southern California Psychiatry Conference

ByJessica Walters

July 30th 2026

Laflor2000/peopleimages.com/Adobe Stock

Making Sense of the New Alzheimer Treatment Landscape, With Aaron Ritter, MD

ByJessica Walters,Aaron Ritter, MD

July 30th 2026

Latest CME

Jersey City Psychiatry

In-Person Event

Jersey City Psychiatry

October 2-3, 2026

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Trending on Psychiatric Times

Postpartum Psychosis on Trial: What the Lindsay Clancy Case Can Teach Us

FDA Approves Oveporexton for Narcolepsy Type 1, First Drug to Treat Full Range of NT1 Symptoms

Centanafadine in ADHD: Clinical Significance of the First Triple Reuptake Inhibitor for ADHD

FAQ: What Clinicians Need to Know About Postpartum Psychosis

How Wearable Tech Can Translate Into Practical Precision Medicine in Psychiatry